May 12, 2006 Henrik S. Rasmussen, M.D., Ph.D.Restricted Stock Agreement • March 15th, 2007 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances)
May 12, 2006 Mr. Joseph JohnsonStock Option Agreement • March 15th, 2007 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances)
SECOND AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 15th, 2007 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances) • Massachusetts
THIS SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT, dated as of the 14th day of November, 2006 (this “Amendment”), is between Nabi Biopharmaceuticals, a Delaware corporation (the “Seller”), and Fresenius USA Manufacturing, Inc., a Delaware corporation (the “Buyer”), and amends the Asset Purchase Agreement (the “Purchase Agreement”), dated as of October 11, 2006, by and between the Buyer and the Seller.
FIRST AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 15th, 2007 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances) • Massachusetts
THIS FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT, dated as of the 31st day of October, 2006 (this “Amendment”), is between Nabi Biopharmaceuticals, a Delaware corporation (the “Seller”), and Fresenius USA Manufacturing, Inc., a Delaware corporation (the “Buyer”), and amends the Asset Purchase Agreement (the “Purchase Agreement”), dated as of October 11, 2006, by and between the Buyer and the Seller.
Braintree Laboratories, Inc. Braintree, MA 02185-0929Asset Purchase Agreement • March 15th, 2007 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances)
Reference is made to the Asset Purchase Agreement dated as of June 23, 2003 (the “Purchase Agreement”) between Braintree Laboratories, Inc. (“Braintree”) and Nabi Biopharmaceuticals (“Nabi”) pursuant to which Braintree sold to Nabi certain assets related to PhosLo® and to the Promissory Note issued by Nabi to Braintree on August 4, 2003 in the original principal amount of $25,000,000 (the “Note”).
NONCOMPETITION AND NONSOLICITATION AGREEMENT between FRESENIUS USA MANUFACTURING, INC. and NABI BIOPHARMACEUTICALS November 14, 2006Noncompetition and Nonsolicitation Agreement • March 15th, 2007 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances)
THIS NONCOMPETITION AND NONSOLICITATION AGREEMENT (this “Agreement”), dated as of November 14, 2006, is between Fresenius USA Manufacturing, Inc., a Delaware corporation, (the “Buyer”), and Nabi Biopharmaceuticals, a Delaware corporation (the “Seller”).
ASSET PURCHASE AGREEMENT between NABI BIOPHARMACEUTICALS (the Seller) and FRESENIUS USA MANUFACTURING, INC. (the Buyer) Dated October 11, 2006Asset Purchase Agreement • March 15th, 2007 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances)
THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated October 11, 2006, is between Nabi Biopharmaceuticals, a Delaware corporation (the “Seller”); and Fresenius USA Manufacturing, Inc., a Delaware corporation (the “Buyer”).
